Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 2057-2063

  Petty, W Jeffrey ^a   Laudadio, Jennifer ^a   Brautnick, Lynsay ^a   Lovato, James ^a   Dotson, Travis ^a   Streer, Nathan P ^a   Weaver, Kathryn E ^a   Miller, Antonius A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclin D1; Cyclin D3; Erlotinib; Pharmacokinetics

Indexed keywords

APREPITANT; BIOLOGICAL MARKER; CISPLATIN; CYCLIN D1; CYCLIN D3; DOCETAXEL; ERLOTINIB; FOSAPREPITANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE DENSIFICATION; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; SMOKING; TIME TO PROGRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYCLIN D1; CYCLIN D3; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SURVIVAL; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891950858     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2122     Document Type: Article

References (23)

1. Miller AA, Wang XF, Gu L, et al: Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol 3: 1159-1165, 2008.
2. Shepherd FA, Rodrigues Pereira J, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
3. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529, 2010.
4. Petrelli F, Borgonovo K, Cabiddu M, et al: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 78: 8-15, 2012.
5. Lee SM, Khan I, Upadhyay S, et al: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13: 1161-1170, 2012.
6. Hughes AN, O'Brien ME, Petty WJ, et al: Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27: 1220-1226, 2009.
7. Jänne PA, Wang X, Socinski MA, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 30: 2063-2069, 2012.
8. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011.
9. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
10. Ling YH, Li T, Yuan Z, et al: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72: 248-258, 2007.
11. Petty WJ, Dragnev KH, Memoli VA, et al: Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10: 7547-7554, 2004.
12. Kobayashi S, Shimamura T, Monti S, et al: Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 66: 11389-11398, 2006.
13. Dragnev KH, Petty WJ, Shah S, et al: Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23: 8757-8764, 2005.
14. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1: 44-53, 2011.
15. Petty WJ, Voelzke WR, Urbanic JJ, et al: High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 74: 384-391, 2011.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
17. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
18. Roche trials database: A study of Tarceva (erlotinib) to compare two different doses in currently smoking patients with advanced or metastatic non-small cell lung cancer (CURRENTS). 〈http://www.roche-trials.com/ trialDetailsGet.action?studyNumber=MO22162〉
19. Parsons A, Daley A, Begh R, et al: Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 340: b5569, 2010.
20. Waller LL, Weaver KE, Petty WJ, et al: Effects of continued tobacco use during treatment of lung cancer. Expert Rev Anticancer Ther 10: 1569-1575, 2010.
21. Brugger W, Triller N, Blasinska-Morawiec M, et al: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29: 4113-4120, 2011.
22. Addison CL, Ding K and Zhao H: Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 28: 5247-5256, 2010.
23. Witta SE, Jotte RM, Konduri K, et al: Randomized phase II trial of erlotinib with and without entinostatin patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 30: 2248-2255, 2012.